PMID- 38468222
OWN - NLM
STAT- MEDLINE
DCOM- 20240313
LR  - 20240314
IS  - 1471-2202 (Electronic)
IS  - 1471-2202 (Linking)
VI  - 25
IP  - 1
DP  - 2024 Mar 11
TI  - Administration methods and dosage of poly(lactic acid)-glycol intervention to 
      myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalitis 
      mice.
PG  - 16
LID - 10.1186/s12868-024-00859-y [doi]
LID - 16
AB  - BACKGROUND: Myelin oligodendrocyte glycoprotein-associated disorders (MOGAD) is 
      an autoimmune central nervous system disease. Antigen-specific immune tolerance 
      using nanoparticles such as Polylactic-co-glycolic acid (PLGA) have recently been 
      used as a new therapeutic tolerization approach for CNS autoimmune diseases. We 
      examined whether MOG(1-125) conjugated with PLGA could induce MOG-specific immune 
      tolerance in an experimental autoimmune encephalitis (EAE) mouse model. EAE was 
      induced in sixty C57BL/6 J wild-type mice using MOG(1-125) peptide with complete 
      Freund's Adjuvant. The mice were divided into 12 groups (n = 5 each) to test the 
      ability of MOG(1-125) conjugated PLGA intervention to mitigate the severity or 
      improve the outcomes from EAE with and without rapamycin compared to antigen 
      alone or PLGA alone. EAE score and serum MOG-IgG titers were compared among the 
      interventions.Kindly check and confirm the processed Affiliation 
      “4” is appropriate.I confirmed the Aff 4.Affiliation: Corresponding 
      author information have been changed to present affiliation. Kindly check and 
      confirm.I checked and confirmed the Corresponding author's information. RESULTS: 
      Mice with EAE that were injected intraperitoneally with MOG(1-125) conjugated 
      PLGA + rapamycin complex showed dose-dependent mitigation of EAE score. 
      Intraperitoneal and intravenous administration resulted in similar clinical 
      outcomes, whereas 80% of mice treated with subcutaneous injection had a 
      recurrence of clinical score worsening after approximately 1 week. Although there 
      was no significant difference in EAE scores between unconjugated-PLGA and 
      MOG-conjugated PLGA, serum MOG-IgG tended to decrease in the MOG-conjugated PLGA 
      group compared to controls. CONCLUSION: Intraperitoneal administration of PLGA 
      resulted in dose-dependent and longer-lasting immune tolerance than subcutaneous 
      administration. The induction of immune tolerance using PLGA may represent a 
      future therapeutic option for patients with MOGAD.
CI  - (c) 2024. The Author(s).
FAU - Wright, Amy E
AU  - Wright AE
AD  - Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.
FAU - Nishiyama, Shuhei
AU  - Nishiyama S
AUID- ORCID: 0000-0002-0248-1595
AD  - Department of Neurology, Massachusetts General Hospital, Boston, MA, USA. 
      snishym@med.tohoku.ac.jp.
AD  - Harvard Medical School, Boston, MA, USA. snishym@med.tohoku.ac.jp.
AD  - , Cambridge, USA. snishym@med.tohoku.ac.jp.
FAU - Han, Patrick
AU  - Han P
AD  - Harvard Medical School, Boston, MA, USA.
FAU - Kong, Philip
AU  - Kong P
AD  - Statera Therapeutics, New Haven, CT, USA.
FAU - Levy, Michael
AU  - Levy M
AD  - Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.
AD  - Harvard Medical School, Boston, MA, USA.
LA  - eng
GR  - R43 AI157959/AI/NIAID NIH HHS/United States
GR  - R43AI157959/NH/NIH HHS/United States
PT  - Journal Article
DEP - 20240311
PL  - England
TA  - BMC Neurosci
JT  - BMC neuroscience
JID - 100966986
RN  - 0 (Myelin-Oligodendrocyte Glycoprotein)
RN  - 459TN2L5F5 (poly(lactide))
RN  - 0 (Glycols)
RN  - W36ZG6FT64 (Sirolimus)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Polyesters)
RN  - Hashimoto's encephalitis
SB  - IM
MH  - Humans
MH  - Mice
MH  - Animals
MH  - Myelin-Oligodendrocyte Glycoprotein/adverse effects
MH  - *Encephalomyelitis, Autoimmune, Experimental/chemically induced/drug therapy
MH  - Mice, Inbred C57BL
MH  - Glycols/adverse effects
MH  - Sirolimus/pharmacology
MH  - Immunoglobulin G/adverse effects
MH  - *Encephalitis
MH  - *Polyesters
MH  - *Hashimoto Disease
PMC - PMC10929165
OTO - NOTNLM
OT  - EAE
OT  - MOG-IgG
OT  - MOGAD
OT  - PLGA
COIS- There is no competing interests to disclose.
EDAT- 2024/03/12 06:42
MHDA- 2024/03/13 06:46
PMCR- 2024/03/11
CRDT- 2024/03/12 01:14
PHST- 2024/01/06 00:00 [received]
PHST- 2024/02/28 00:00 [accepted]
PHST- 2024/03/13 06:46 [medline]
PHST- 2024/03/12 06:42 [pubmed]
PHST- 2024/03/12 01:14 [entrez]
PHST- 2024/03/11 00:00 [pmc-release]
AID - 10.1186/s12868-024-00859-y [pii]
AID - 859 [pii]
AID - 10.1186/s12868-024-00859-y [doi]
PST - epublish
SO  - BMC Neurosci. 2024 Mar 11;25(1):16. doi: 10.1186/s12868-024-00859-y.